Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Eotaxin (CCL11) is a member of the CC chemokine family that is critically involved in the recruitment of eosinophils, especially in response to allergens[1][5]. It exerts its function primarily by binding to the chemokine receptor CCR3, which is highly expressed on eosinophils, leading to their migration to sites of allergic inflammation. Eotaxin plays a significant role in the pathogenesis of asthma and other chronic inflammatory respiratory conditions[1][2][4][5]. It is a small, secreted protein (chemokine) of about 74 amino acids, structurally characterized by a conserved chemokine fold stabilized by disulfide bonds[1].
Antagonism or inhibition of Eotaxin-CCR3 binding to prevent eosinophil recruitment and activation[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Eotaxin (CCL11) (CCL11).